Thalassemia

pharma-news-for-agios-bridgebio-rigel

Jan 14, 2025

Agios’ PYRUKYND SNDA Accepted by FDA for Thalassemia; BridgeBio’s BBO-8520 Gets FDA Fast Track for KRASG12C-Mutated Lung Cancer; Nipocalimab Granted FDA Priority Review for Myasthenia Gravis; Rigel’s R289 Receives FDA Orphan Drug Designation for MDS; Rise Therapeutics Gets FDA IND Clearance for R-5780 in Cancer

pharma-news-for-sandoz-agios-organon-bms-sanofi-bayer-lilly

Feb 22, 2022

Sandoz’s Generic Revlimid; Agios’ Pyrukynd; Organon Announces 4Q & Full-year Earnings Report; BMS’ CAR-T Drug Breyanzi; Sanofi & Regeneron’s Dupixent Trial; AZ & Daiichi’s Drug Enhertu; Bayer’s Drug Kerendia; Lilly Releases Mirikizumab Data

Beta-Thalassemia-Market

May 08, 2020

Overcoming the prevailing unmet needs in Beta-Thalassemia Market

Beta Thalassemia Pharmacological Therapies

Nov 13, 2019

Beta-Thalassemia Pharmacological Therapies

Pharma news

Nov 12, 2019

FDA declines the approval of Lipocine’s testosterone drug; Novartis Sandoz to buy Aspen Pharmacare Japanese Unit

Companion Diagnostics

Sep 28, 2018

Companion Diagnostics

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper